Fol­low­ing $1.9B buy­out, Sanofi shut­ters Kad­mon's NY site and chops 25 staffers

Sanofi CEO Paul Hud­son is on a mis­sion to re­shape the com­pa­ny. Last year, that in­volved shelling out $1.9 bil­lion for Kad­mon and its new­ly ap­proved Rezurock — but ap­par­ent­ly, the for­mer biotech’s New York site is not part of Hud­son’s vi­sion.

The phar­ma gi­ant is shut­ting down Kad­mon’s New York plant in Q3 and lay­ing off 25 em­ploy­ees, ac­cord­ing to New York state doc­u­ments. The lay­offs will be­gin Ju­ly 1, and con­tin­ue through April 1, 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER